Tags : tildrakizumab

Sun Pharma Signs a License Agreement with Hikma for Ilumya

Shots: SunPharma to receive upfront and milestones for licensing its product to Hikma and will supply Ilumya.  Hikma will be responsible for the registration and commercialization of the product in all MENA markets Hikma’s presence in the MENA region will enable access to a new treatment option for people who are unable to manage their […]Read More

Sun Pharma Reports Submission of Manufacturing and Marketing Authorization Application

Shots: Sun Pharma has filed manufacturing and marketing authorization of Tildrakizumab to the PMDA for moderate-to-severe psoriasis and psoriatic arthritis in Japan Additionally, Sun Pharma has acquired Pola Pharma and will leverage Pola’s strong presence in the dermatology to commercialize Tildrakizumab in Japan which will expand Sun Pharma’s global franchise and robust its dermatology pipeline […]Read More

NICE Publishes Final Recommendation for Almirall’s Ilumetri (tildrakizumab) to Treat

Shots: NICE has recommended Ilumetri (tildrakizumab) as a cost-effective option for the treatment of adults patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy following its assessment submission in Aug’18 Ilumetri (tildrakizumab) is evaluated in P-III reSURFACE 1 and 2 study in 1,800 patients > 200 sites across the globe resulted in maintaining […]Read More

Almirall’s Ilumetri (tildrakizumab) Receives NICE’s Provisional Approval for Moderate-To-Severe Plaque

Shots: The approval is based on P-III reSURFACE 1 & reSURFACE 2 studies assessing Ilumetri (tildrakizumab) in 1,800 patients with moderate-to-severe plaque psoriasis across 200 sites WW reSURFACE 1 & reSURFACE 2 studies result: @12wks. PASI 75 (75%); @28wks. PASI 90 (54%), PASI 100 (29%); well tolerated; low AEs & discontinuation rates Ilumetri (tildrakizumab, SC, […]Read More